Emerging Opportunities in Multiple Sclerosis and Neurosciences



Emerging Opportunities in Multiple Sclerosis and Neurosciences

10:30am – 12:30pm EDT | 4:30pm – 6:30pm CET | September 24, 2020

Register Now

Can we build a roadmap to conquer Multiple Sclerosis (MS), a disease that impacts more than 2 million globally as the leading non-traumatic disability disorder in young adults? How have lessons learnt so far shed light on broader neuroscience R&D?

On September 24, join us for "Emerging Opportunities in Multiple Sclerosis and Neurosciences," the fourth episode in our "Collaborations That Transform" webinar series.


AGENDA (Eastern Daylight Time)



Hui Cai, VP and Head of Content, WuXi AppTec, Program Chair

10:30 – 10:50

Session I: Meeting the Challenges in MS and Neuroscience Drug Development

A conversation with Dietmar Berger, Head of Development and CMO, Sanofi; moderated by Kevin Da Silva, Chief Editor, Nature Neuroscience

10:50 – 11:35

Session II: Clinical Prospects for a Challenging Disease

Tanuja Chitnis, Professor of Neurology, Harvard Medical School; Director, Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital

Mark Freedman, Professor of Neurology, University of Ottawa; Sr. Scientist, The Ottawa Hospital Research Institute

Ari Green, Chief, Division of Neuroinflammation and Glial Biology, Medical Director, Multiple Sclerosis and Neuroinflammation Center, UCSF

Cyndi Zagieboylo, President and CEO, National MS Society

Moderated by Mandy Jackson, Managing Editor of US Commercial News for Scrip and The Pink Sheet

11:35 – 12:30

Session III: New Directions in MS Therapies

Joachim Herz, Professor, Molecular Genetics, Neuroscience, Neurology; Director, Center for Translational Neurodegeneration Research, UT Southwestern Medical Center

Ralph Kern, President and Chief Medical Officer, Brainstorm Cell Therapeutics

Dan Lorrain, Chief Scientific Officer, Pipeline Therapeutics

Krish Ramanathan, Global Program Head, Neuroscience and Global Drug Development, Novartis

Moderated by Richard Soll, Head of WuXi AppTec's Boston office; Senior Advisor of Strategic Initiatives



Please click HERE to view speaker bios and register. This event is complimentary and open to the public.

As an industry enabler, WuXi AppTec is committed to improving the lives of patients globally. We share the conviction that we must work collaboratively to solve industry-wide challenges and bring transformative medicines to patients.

We welcome you to the conversation.

Register Now